Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Gainers Galecto (NASDAQ: GLTO) stock rose 21.6% to $5.41 during Thursday's after-market session. The market value of their...
Cantor Fitzgerald analyst Olivia Brayer initiates coverage on CytomX Therapeutics (NASDAQ:CTMX) with a Overweight rating and...
- The CTMX-2051-101 study has enrolled 73 colorectal cancer patients to-date, aligned with the Company's goal of providing ...
-SECFiling
CytomX Therapeutics (NASDAQ:CTMX) reported quarterly sales of $18.658 million which beat the analyst consensus estimate of $14....
